Skip to main content

Advertisement

Table 5 Mean life time health outcomes, costs and average and incremental cost-effectiveness ratios (CERs) for the drug combinations in a scenario with very high CV risk. Incremental CERs are in addition reported for the high, medium and low CV risk scenarios. 95% confidence intervals are reported in brackets for the ICERs.

From: Cost-effectiveness of medical interventions to prevent cardiovascular disease in a sub-Saharan African country – the case of Tanzania

  Very high CV risk Incremental CERs (USD/DALY)
Intervention Life years saved (nominal) Costs DALYs ACER (USD/DALY) ICER (USD/DALY) High risk Medium risk Low risk
Asa 1.6 138 0.8 163 (Dominated)    
DiuVhigh 1.6 74 0.9 85 85 (61 – 133) 135 (95 – 212) 149 (105 – 230) 232 (163 – 266)
Bet 0.6 107 0.3 329 (Dominated)    
Cab 0.7 444 0.4 1095 (Dominated)    
Sta 2.7 882 1.6 540 (Dominated)    
AsaDiu 3.1 175 1.6 111 143 (108 – 197) 222 (146 – 314) 242 (182 – 337) 377 (280 – 530)
AsaBet 2.2 208 1.1 182 (Dominated)    
DiuBet 2.2 141 1.1 124 (Dominated)    
AsaDiuBet 3.6 250 1.8 138 317 (169 – 3900) 532 (265 – *) 601 (305 – *) 1009 (465 – *)
AsaDiuSta 4.9 1123 2.6 431 (Dominated)    
DiuBetSta 4.6 1086 2.5 433 (Dominated)    
AsaBetSta 4.4 1143 2.4 481 (Dominated)    
AsaDiuBetSta 5.4 1229 2.8 440 999 (752 – 1376) 1588 (1175–2190) 1739 (1270–2420) 2749 (2010–3850)
Poly 6.3 1755 3.2 557 1476 (545–8000) 2466 (856–16800) 2735 (932–19500) 4589 (1450–51000)
  1. * > 100 000